User login
Key clinical point: Patients with psoriatic arthritis (PsA) showed similar adherence to secukinumab and ixekizumab as first-line or second-line interleukin (IL)-17A inhibitors, which indicates that the failure of a first-line IL-17A inhibitor therapy should not deter treatment with a second-line IL-17A inhibitors.
Major finding: Similar adherence to treatment was observed between first-line and second-line IL-17A inhibitor switchers and between second-line secukinumab and second-line ixekizumab switchers. Withdrawal reasons were similar for both first-line and second-line switchers when considering adverse events (14% for both); however, withdrawal due to failure of therapy was higher for the first-line vs second-line switchers (34% vs 18%).
Study details: Findings are from a population-based cohort study including patients with PsA who underwent prior treatment with ≥ 1 tumor necrosis factor inhibitor and switched to either first-line (n = 534) or second-line (n = 102) IL-17A inhibitors (ixekizumab or secukinumab).
Disclosures: This study was funded by the Oak Foundation. Five authors declared having ties with various sources, and three authors declared no conflicts of interest.
Source: Hansen RL et al. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study. Rheumatology (Oxford). 2023 (Aug 30). doi: 10.1093/rheumatology/kead434
Key clinical point: Patients with psoriatic arthritis (PsA) showed similar adherence to secukinumab and ixekizumab as first-line or second-line interleukin (IL)-17A inhibitors, which indicates that the failure of a first-line IL-17A inhibitor therapy should not deter treatment with a second-line IL-17A inhibitors.
Major finding: Similar adherence to treatment was observed between first-line and second-line IL-17A inhibitor switchers and between second-line secukinumab and second-line ixekizumab switchers. Withdrawal reasons were similar for both first-line and second-line switchers when considering adverse events (14% for both); however, withdrawal due to failure of therapy was higher for the first-line vs second-line switchers (34% vs 18%).
Study details: Findings are from a population-based cohort study including patients with PsA who underwent prior treatment with ≥ 1 tumor necrosis factor inhibitor and switched to either first-line (n = 534) or second-line (n = 102) IL-17A inhibitors (ixekizumab or secukinumab).
Disclosures: This study was funded by the Oak Foundation. Five authors declared having ties with various sources, and three authors declared no conflicts of interest.
Source: Hansen RL et al. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study. Rheumatology (Oxford). 2023 (Aug 30). doi: 10.1093/rheumatology/kead434
Key clinical point: Patients with psoriatic arthritis (PsA) showed similar adherence to secukinumab and ixekizumab as first-line or second-line interleukin (IL)-17A inhibitors, which indicates that the failure of a first-line IL-17A inhibitor therapy should not deter treatment with a second-line IL-17A inhibitors.
Major finding: Similar adherence to treatment was observed between first-line and second-line IL-17A inhibitor switchers and between second-line secukinumab and second-line ixekizumab switchers. Withdrawal reasons were similar for both first-line and second-line switchers when considering adverse events (14% for both); however, withdrawal due to failure of therapy was higher for the first-line vs second-line switchers (34% vs 18%).
Study details: Findings are from a population-based cohort study including patients with PsA who underwent prior treatment with ≥ 1 tumor necrosis factor inhibitor and switched to either first-line (n = 534) or second-line (n = 102) IL-17A inhibitors (ixekizumab or secukinumab).
Disclosures: This study was funded by the Oak Foundation. Five authors declared having ties with various sources, and three authors declared no conflicts of interest.
Source: Hansen RL et al. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: A Danish population-based cohort study. Rheumatology (Oxford). 2023 (Aug 30). doi: 10.1093/rheumatology/kead434